Guidant Likely Will Bow Out Of AAA Race As Stakes Rise Too High
This article was originally published in The Gray Sheet
Executive Summary
Guidant is poised to exit the abdominal aortic aneurysm market, which could eventually reach $1 bil., citing declining sales and a lack of adoption by vascular surgeons of its Ancure AAA endovascular stent graft
You may also be interested in...
Guidant/EVT Lesson Learned: Post Senior Compliance Execs To Acquired Unit
Integration of a parent firm's adverse event reporting and compliance structure into a subsidiary should begin immediately upon acquisition, as illustrated by Guidant's experience with Menlo Park, Calif. unit Endovascular Technologies
Guidant/EVT Lesson Learned: Post Senior Compliance Execs To Acquired Unit
Integration of a parent firm's adverse event reporting and compliance structure into a subsidiary should begin immediately upon acquisition, as illustrated by Guidant's experience with Menlo Park, Calif. unit Endovascular Technologies
Cordis Stresses Durability Of Fortron AAA System, European Safety Results
The positive safety profile of Johnson & Johnson/ Cordis' Fortron abdominal aortic aneurysm (AAA) stent graft, as demonstrated in Europe, likely will be a key component of the firm's U.S. marketing strategy